DECHENG CAPITAL LLC

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/28/2024

Adviser Type:

- Large advisory firm

Number of Employees:

21 16.67%

of those in investment advisory functions:

14 16.67%

Registration:

SEC, Approved, 4/30/2020

Other registrations (2)
Former registrations

DECHENG CAPITAL LLC

AUM:

1,977,628,753 9.71%

of that, discretionary:

1,977,628,753 9.71%

GAV:

1,790,299,187 17.80%

Avg Account Size:

282,518,393 -21.63%

SMA’s:

NO

Private Funds:

5

Contact Info

345 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
2B 2B 2B 1B 947M 631M 316M
2020 2021 2022 2023

Recent News

China Digest: PackGene Biotech, AI chip startup Axera close fresh funding
04/07/2021

Return backers Sequoia Capital China, Cathay Capital China, Kaitai Capital, Oriza Seed, and Decheng Capital re-upped in the current round ... A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across ...

dealstreetasia.com

Alpine Immune Sciences Inc.
04/03/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
04/02/2021

LA JOLLA, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory ...

Yahoo Finance

BeyondSpring Inc.
03/29/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
03/28/2021

LA JOLLA, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter ...

Yahoo Finance

Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update Nasdaq:EQ
03/25/2021

Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple data and regulatory catalysts in 2021 LA JOLLA, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Equillium,

menafn.com


Private Funds Structure

Fund Type Count GAV
Hedge Fund 1 $165,684,528
Venture Capital Fund 4 $1,624,614,659

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
LOGOS GLOBAL MANAGEMENT, L.P. 957.8m - - - - 547.9m - 2.1b 1.5b 6
COINFUND MANAGEMENT LLC 297.1m - - - - 608.9m - 1.5b 906.1m 10
MADERA TECHNOLOGY ADVISORS, LLC 21.7m - - - - 78.8m - 179.2m - 5
BULL & BEAR, LP 36.7m - - - - 43.0m - 122.7m - 6
RA CAPITAL MANAGEMENT, LP 9.4b - - - - 1.9b - 13.1b 11.3b 5
AMITY VENTURES, LLC 31.7m - - - - 892.4m - 1.8b 1.1b 18
STANDARD CRYPTO MANAGEMENT LP 643.2m - - - - 505.0m - 1.7b 1.1b 4
ALTIMETER CAPITAL MANAGEMENT, LP 6.2b - - - - 4.5b - 15.2b 10.7b 19
CRCM L.P. 188.0m - - - - 351.9m - 891.9m 546.9m 9
ATREIDES MANAGEMENT, LP 3.9b - - - - 462.3m - 4.8b 4.7b 17

Private Funds



Employees




Brochure Summary

Overview

Advisory Business A. Decheng was founded in 2011 and is principally owned by its Managing Member, Xiangmin (“Min”) Cui. Historically, the Firm’s venture-oriented strategy focused on providing capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. Over the years, Decheng has evolved into a stage-agnostic investor, targeting companies of varying maturation – from incubation-phase businesses to publicly-traded issuers. B. Decheng provides investment management services to pooled investment vehicles (each a “Fund” or “Client” and collectively the “Funds” or “Clients”), which are sponsored by affiliates of Decheng that serve as the general partner to the limited partnerships (the “General Partner”). Interests in the Funds are privately offered to qualifying investors pursuant to Regulation D under the Securities Act of 1933, as amended (“Securities Act”), and each Fund qualifies for an exclusion from registration under Section 3(c)(7) of the Investment Company Act of 1940, as amended (“Investment Company Act”). As of the date of this Brochure, the Funds include: ▪ Decheng Capital China Life Sciences USD Fund I, L.P. ▪ Decheng Capital China Life Sciences USD Fund II, L.P. ▪ Decheng Capital China Life Sciences
USD Fund III, L.P. ▪ Decheng Capital Global Life Sciences Fund IV, L.P. ▪ Decheng Global Healthcare Fund (Master), LP The Funds are subject to the investment objectives, terms and conditions outlined in their respective offering documents which depending on the Fund include the summary of principal terms, limited partnership agreement, private placement memorandum, subscription documents and/or investment management agreement. Collectively, these documents are referred to herein as the “Governing Documents.” While Decheng focuses on the strategies discussed throughout the Brochure, the Firm does not necessarily limit the types of investments on which it advises. C. To the extent agreed upon in the Governing Documents, Decheng tailors its investment advisory services to be consistent with each Fund’s investment strategy, return profile, concentration limits, time horizon, liquidity mandates and other related objectives, as defined therein. Underlying investors may not impose restrictions on investing in certain securities or types of securities. D. Decheng does not participate as a sponsor of or portfolio manager to any wrap fee programs. E. As of December 31, 2022, the Firm had approximately $1,802,579,659 in assets under management, all of which was managed on a discretionary basis.